The lung immune prognostic index (LIPI) is recently developed to predict immune checkpoint inhibitors (ICIs) treatment outcomes for non-small cell lung cancer. However, its predictive value for other types of cancer remained unclear. This meta-analysis aimed to evaluate the association between pretreatment LIPI score and therapeutic outcomes in cancer patients treated with ICIs.

We searched PubMed, Cochrane Library literature databases and EMBASE for abstracts and full-text articles published from the inception of the database until 16th, Nov 2020. Meta-analyses were performed separately for progression-free survival (PFS) and overall survival (OS) by using the random-effects model.

A total of 12 studies involving 4883 patients receiving ICIs treatment were identified for the primary analysis. The pooled results implied that compared with good LIPI score groups, patients with poor or intermediate LIPI score were significantly associated with worse OS (HR=3.33, 95%CI 2.64-4.21, P < 0.001, I² = 64.2%; HR=1.71, 95%CI 1.43-2.04, P < 0.001, I² = 43.6%, respectively) and PFS (HR=2.73,95%CI 2.00-3.73, P < 0.001, I² = 78.2%; HR=1.43, 95%CI 1.28-1.61, P < 0.001, I² = 16.3%, respectively). Also, for 1873 patients receiving chemotherapy, a poor LIPI score was significantly associated with worse OS (HR=2.30, 95%CI 1.73-3.07, P < 0.001; I² = 56.2%) and PFS (HR=1.92,95%CI 1.69-2.17; P < 0.001; I² = 0.0%) compared with good LIPI score groups.

A good LIPI score was significantly correlated with improved OS and PFS in cancer patients receiving ICIs or chemotherapy, regardless of the types of cancer.

最近开发的肺免疫预后指数 (LIPI) 用于预测非小细胞肺癌的免疫检查点抑制剂 (ICI) 治疗结果。然而，它对其他类型癌症的预测价值仍不清楚。这项荟萃分析旨在评估接受 ICI 治疗的癌症患者的治疗前 LIPI 评分与治疗结果之间的关联。

我们在 PubMed、Cochrane 图书馆文献数据库和 EMBASE 中搜索了从数据库成立到 2020 年 11 月 16 日发表的摘要和全文文章。分别对无进展生存期 (PFS) 和总生存期 (OS) 进行了荟萃分析通过使用随机效应模型。

共有 12 项研究被确定为主要分析，涉及 4883 名接受 ICIs 治疗的患者。汇总结果表明，与 LIPI 评分良好的组相比，LIPI 评分较差或中等的患者与较差的 OS 显着相关（HR=3.33，95%CI 2.64-4.21，P < 0.001，I ² = 64.2%；HR=1.71 , 95%CI 1.43-2.04, P < 0.001, I ² = 43.6%) 和 PFS (HR=2.73,95%CI 2.00-3.73, P < 0.001, I ² = 78.2%; HR=1.43, 95% CI 1.28-1.61，P < 0.001，I ² = 16.3%，分别）。此外，对于 1873 名接受化疗的患者，较差的 LIPI 评分与较差的 OS（HR=2.30，95%CI 1.73-3.07，P < 0.001；I ² = 56.2%）和 PFS（HR=1.92，95%CI）显着相关1.69-2.17；P < 0.001；I² = 0.0%) 与良好的 LIPI 评分组相比。

无论癌症类型如何，良好的 LIPI 评分与接受 ICI 或化疗的癌症患者的 OS 和 PFS 改善显着相关。